Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Byrd

Showing results (781-790 of 903) with videos related to

Pageof 91
Sort By:
Nature Cancer|December 29, 2022
An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemiaAudrey Lasry, Bettina Nadorp, Maarten Fornerod, et al.
Cell Reports|July 20, 2022
Leukemia-initiating HSCs in chronic lymphocytic leukemia reveal clonal leukemogenesis and differential drug sensitivityChi-Ling Chiang, Eileen Y Hu, Lingqian Chang, et al.
Blood|March 12, 2014
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemiaJennifer R Brown, John C Byrd, Steven E Coutre, et al.
Blood|April 5, 2017
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLLPaul M Barr, Jennifer R Brown, Peter Hillmen, et al.
JAMA Oncology|July 17, 2015
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic LeukemiaKami J Maddocks, Amy S Ruppert, Gerard Lozanski, et al.
Leukemia|March 16, 2007
International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemiaA C Rawstron, N Villamor, M Ritgen, et al.
Plos One|June 10, 2010
The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivoDavid M Lucas, Lapo Alinari, Derek A West, et al.
JCI Insight|December 3, 2020
TP-0903 is active in models of drug-resistant acute myeloid leukemiaJae Yoon Jeon, Daelynn R Buelow, Dominique A Garrison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2025
Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib StudyKerry A Rogers, Pearlly Yan, Ian W Flinn, et al.
Blood|October 24, 2002
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)John C Byrd, Krzysztof Mrózek, Richard K Dodge, et al.
Pageof 91

Showing results (781-790 of 903) with videos related to

Sort By:
Pageof 91
Nature Cancer|December 29, 2022
An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemiaAudrey Lasry, Bettina Nadorp, Maarten Fornerod, et al.
Cell Reports|July 20, 2022
Leukemia-initiating HSCs in chronic lymphocytic leukemia reveal clonal leukemogenesis and differential drug sensitivityChi-Ling Chiang, Eileen Y Hu, Lingqian Chang, et al.
Blood|March 12, 2014
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemiaJennifer R Brown, John C Byrd, Steven E Coutre, et al.
Blood|April 5, 2017
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLLPaul M Barr, Jennifer R Brown, Peter Hillmen, et al.
JAMA Oncology|July 17, 2015
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic LeukemiaKami J Maddocks, Amy S Ruppert, Gerard Lozanski, et al.
Leukemia|March 16, 2007
International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemiaA C Rawstron, N Villamor, M Ritgen, et al.
Plos One|June 10, 2010
The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivoDavid M Lucas, Lapo Alinari, Derek A West, et al.
JCI Insight|December 3, 2020
TP-0903 is active in models of drug-resistant acute myeloid leukemiaJae Yoon Jeon, Daelynn R Buelow, Dominique A Garrison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2025
Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib StudyKerry A Rogers, Pearlly Yan, Ian W Flinn, et al.
Blood|October 24, 2002
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)John C Byrd, Krzysztof Mrózek, Richard K Dodge, et al.
Pageof 91